---
title: BioIntel
emoji: 🧬
colorFrom: blue
colorTo: green
sdk: gradio
sdk_version: 6.30.0
app_file: app.py
pinned: false
license: mit
short_description: Biotech catalysts from SEC filings and trials
---

# BioIntel

Biotech catalyst intelligence built entirely from public sources.

| Tab | What it shows |
|---|---|
| **Catalyst feed** | SEC 8-K filings matching 12 clinical/regulatory signal types — what already happened |
| **Readout calendar** | Industry trials with a primary completion date ahead — dated catalysts that have not happened yet |
| **Demand mix** | Modality mix of the upcoming pipeline, the closest public read on future wet-lab and manufacturing need |

## Sources

- **SEC EDGAR full-text search** (`efts.sec.gov`) — no key, 10 req/s ceiling, descriptive User-Agent required
- **ClinicalTrials.gov API v2** — no key

Data is refreshed by a scheduled job and published as parquet to a Hugging Face
Dataset repo, which this Space reads at startup.

## Method notes

Catalyst phrases were chosen by **measurement rather than assumption**. Over a
sample window, `"met its primary endpoint"` appeared in 54 filings while
`"met the primary endpoint"` appeared in 19, and `"topline data"` outranked
`"topline results"` — so each signal searches a group of variants. EDGAR
accepts uppercase `OR` between quoted phrases; a `|` silently returns zero.

Both APIs truncate silently: one EDGAR call returns at most 100 hits
regardless of the reported total, and filtering trials client-side after a
truncated fetch drops most of the result set. Both are paged and filtered
server-side here.

## Limitations

Signals co-occur — one filing can match both *endpoint met* and *endpoint
missed*, which is a real reporting pattern, not a bug. Trial completion dates
are plans and slip. Modality is inferred and reports `unknown` rather than
guessing. CRO lab occupancy, private lease terms and options flow are **not**
obtainable from public data.

**An information tool built on public filings. Not investment advice.**